Protalix BioTherapeutics to Present at the 32nd Annual J.P. Morgan Healthcare Conference CARMIEL, Israel, Jan. 7, 2014 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that Dr. David Aviezer, the Company's President and Chief Executive Officer, will present at the 32nd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2014 at 12:00 PM, Pacific Time. The conference will be held at the Westin St. Francis Union Square Hotel in San Francisco on January 13-16, 2014. A live webcast of the presentation will be available at www.protalix.com on the event calendar page. A replay will be archived and available after the conclusion of the presentation for 90 days. About Protalix Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®.Protalix's unique expression system presents a proprietary method for developing recombinant proteins in a cost-effective, industrial-scale manner.Protalix's first product manufactured by ProCellEx, taliglucerase alfa, was approved for marketing by theU.S. Food and Drug Administration (FDA) inMay 2012, byIsrael'sMinistry of HealthinSeptember 2012, by theBrazilian National Health Surveillance Agency(ANVISA) inMarch 2013, by theMexican Federal Commission for the Protection against Sanitary Risk (COFEPRIS) inApril 2013, and by the regulatory authorities of other countries.Marketing applications for taliglucerase alfa have been filed in additional territories as well. Protalix has partnered withPfizer Inc.for the worldwide development and commercialization of taliglucerase alfa, excludingIsraelandBrazil, where Protalix retains full rights. Protalix's development pipeline also includes the following product candidates: PRX-102, a modified version of the recombinant human alpha-GAL-A protein for the treatment of Fabry disease; PRX-112, an orally-delivered glucocerebrosidase enzyme that is produced and encapsulated within carrot cells, also for the treatment of Gaucher disease; pr-antiTNF, a similar plant cell version of etanercept (Enbrel®) for the treatment of certain immune and inflammatory diseases, such as rheumatoid arthritis, Chrohn's disease, colitis, psoriasis and other autoimmune and inflammatory disorders; PRX-110 for the treatment of Cystic Fibrosis; PRX-107 for the treatment of emphysema due to hereditary alpha1-antitrypsin deficiency; and others. CONTACT: Investor Contact Marcy Nanus The Trout Group, LLC 646-378-2927 email@example.com Media Contact Kari Watson MacDougall Biomedical Communications 781-235-3060 firstname.lastname@example.org
Protalix BioTherapeutics to Present at the 32nd Annual J.P. Morgan Healthcare Conference
Press spacebar to pause and continue. Press esc to stop.